Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
23 hedge funds and large institutions have $1.33M invested in Aptose Biosciences, Inc. in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
15% more funds holding
Funds holding: 20 → 23 (+3)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
35% less capital invested
Capital invested by funds: $2.06M → $1.33M (-$728K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$88.8K |
| 2 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$84.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$67.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$15.4K |
| 5 |
AC
Annandale Capital
Dallas,
Texas
|
+$13.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TWC
TD Waterhouse Canada
Toronto,
Ontario, Canada
|
-$3.49K |
| 2 |
OP
ORG Partners
Roanoke,
Indiana
|
-$2.98K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$244 |
| 4 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
-$15 |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$1 |
APTO Hedge Fund Activity: Q3 2024 in Review
23 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2024, worth a combined $1.33M — down 35% from $2.06M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new APTO positions and 1 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Armistice Capital, adding an estimated $88.8K. The largest seller was TD Waterhouse Canada, cutting an estimated $3.49K.
- 23 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2024, up from 20 in Q2 2024.
- Funds reported $1.33M of Aptose Biosciences, Inc. stock for Q3 2024, down 35% quarter-over-quarter.
- 4 funds opened new Aptose Biosciences, Inc. positions in Q3 2024 and 1 closed out, a net change of +3 holders.
- The largest Aptose Biosciences, Inc. buyer in Q3 2024 was Armistice Capital, an estimated $88.8K added.
- The largest Aptose Biosciences, Inc. seller in Q3 2024 was TD Waterhouse Canada, an estimated $3.49K sold.
Based on aggregated 13F filings for Q3 2024.